Benefits and Risks Associated With Continuation of Anti–Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease

Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti‐TNF: a French nationwide study 2010–2018

(2021) Antoine Meyer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor

(2021) Antoine Meyer et al.   Clinical Gastroenterology and Hepatology

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

(2021) Barbra A. Dickerman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changing Global Epidemiology of Inflammatory Bowel Diseases—Sustaining Healthcare Delivery into the 21st Century

(2020) Ashwin N. Ananthakrishnan et al.   Clinical Gastroenterology and Hepatology

Reflections on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data

(2020) Camille Maringe et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy

(2020) Gabriella Bröms et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life

(2020) Shannon Linda Kanis et al.   GUT

Study Designs for Extending Causal Inferences from a Randomized Trial to a Target Population

(2020) Issa J Dahabreh et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

(2020) Uma Mahadevan et al.   GASTROENTEROLOGY

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes

(2019) Mette Julsgaard et al.   INFLAMMATORY BOWEL DISEASES

Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease

(2019) Brindusa Truta et al.   INFLAMMATORY BOWEL DISEASES

Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION)

(2018) Maxime Luu et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

(2018) M Chaparro et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

(2018) Julien Kirchgesner et al.   GASTROENTEROLOGY

How to estimate the effect of treatment duration on survival outcomes using observational data

(2018)   BMJ-British Medical Journal

How to estimate the effect of treatment duration on survival outcomes using observational data

(2018)   BMJ-British Medical Journal

Health-Risk Behaviors and Chronic Conditions Among Adults with Inflammatory Bowel Disease — United States, 2015 and 2016

(2018) Fang Xu et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight

(2017) Heidi Kammerlander et al.   INFLAMMATORY BOWEL DISEASES

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France

(2017) P. Tuppin et al.   REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.

(2016) Miguel A. Hernán et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

(2016) Mette Julsgaard et al.   GASTROENTEROLOGY

The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy

(2016) Geoffrey C. Nguyen et al.   GASTROENTEROLOGY

Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses

(2016) Miguel A. Hernán et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database

(2016) Line Sahli et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Inflammatory Bowel Disease: A Canadian Burden of Illness Review

(2016) Angela Rocchi et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety

(2015) A de Lima et al.   GUT

Bias from conditioning on live birth in pregnancy cohorts: an illustration based on neurodevelopment in children after prenatal exposure to organic pollutants

(2015) Zeyan Liew et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease

(2014) M. Seirafi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Qualité des données périnatales issues du PMSI : comparaison avec l’état civil et l’enquête nationale périnatale 2010

(2013) C. Quantin et al.   JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION

Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease

(2012) Uma Mahadevan et al.   Clinical Gastroenterology and Hepatology

Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model

(2009) Peter C. Austin   JOURNAL OF CLINICAL EPIDEMIOLOGY